=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 X,OH,H

Structure attributes must be viewed using STN Express query preparation.

=> d his

(FILE 'HOME' ENTERED AT 09:57:05 ON 16 JAN 2008)

FILE 'REGISTRY' ENTERED AT 09:57:53 ON 16 JAN 2008
L1 STRUCTURE UPLOADED
L2 QUE L1
L3 2 S L1
L4 40 S L1 FUL
L5 30 S L4 AND CAPLUS/LC
L6 10 S L4 NOT L5

FILE 'CAPLUS' ENTERED AT 10:00:51 ON 16 JAN 2008
L7 18 S L4
L8 14 S L4/THU
L9 15 S L7 AND (GAST?)
L10 1 S L9 AND FUND?
L11 1 S L7 AND (BLOAT? OR ACCOMMADAT? OR PYLORIC?)
L12 1 S L11 NOT L10
L13 3 S L7 AND (DYSPEP? OR INDIGEST?)
L14 2 S L13 NOT (L10 OR L12)
L15 1 S L7 AND SATIE?
L16 0 S L15 NOT (L10 OR L12)
L17 14 S L7 NOT (L10 OR L12 OR L14)

1/16/08

L3 ANSWER 1 OF 1 SCISEARCH COPYRIGHT (c) 2008 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:274371 SCISEARCH
THE GENUINE ARTICLE: 657TV
TITLE: Z-338. Treatment of non-ulcer dyspepsia.
AUTHOR: **Sorbera L A (Reprint)**; Castaner J; Leeson P A
CORPORATE SOURCE: Prous Sci, POB 540, Barcelona 08080, Spain (Reprint); Prous Sci, Barcelona 08080, Spain
COUNTRY OF AUTHOR: Spain
SOURCE: DRUGS OF THE FUTURE, (**JAN 2003**) Vol. **28**, No. **1**, pp. **26**-30.
ISSN: 0377-8282.
PUBLISHER: PROUS SCIENCE, SA, PO BOX 540, PROVENZA 388, 08025 BARCELONA, SPAIN.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 30
ENTRY DATE: Entered STN: 11 Apr 2003
Last Updated on STN: 11 Apr 2003

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB Research efforts focusing on discovering gastroprokinetic agents with mechanisms of action different from available compounds have identified Z-338, a 2-(acylamino)thiazole-4-carboxamide derivative, as having potent gastroprokinetic activity and an excellent safety profile. Results from preclinical studies demonstrated that Z-338 enhances spontaneous contractions and electrically stimulated excitatory junction potentials and acetylcholine release, possibly through inhibition of muscarinic M-1 and M-2 autoreceptors and possibly an M5-like receptor. Z-338 has been shown to be safe in phase I trials involving healthy volunteers in Europe and Japan and in an early phase II trial conducted in patients with functional dyspepsia. Z-338 continues to undergo phase II development.

L14 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:287963 CAPLUS <<LOGINID::20080116>>
DOCUMENT NUMBER: 139:30058
TITLE: Z-338: treatment of non-ulcer dyspepsia
AUTHOR(S): Sorbera, L. A.; Castaner, J.; Leeson, P. A.
CORPORATE SOURCE: Prous Science, Barcelona, 08080, Spain
SOURCE: Drugs of the Future (2003), 28(1), 26-30
CODEN: DRFUD4; ISSN: 0377-8282
PUBLISHER: Prous Science
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English

AB A review. Research efforts focusing on discovering gastroprokinetic agents with mechanisms of action different from available compds. have identified Z-338, a 2-(acylamino)thiazole-4-carboxamide derivative, as having potent gastroprokinetic activity and an excellent safety profile. Results from preclin. studies demonstrated that Z-338 enhances spontaneous contractions and elec. stimulated excitatory junction potentials and acetylcholine release, possibly through inhibition of muscarinic M1 and M2 autoreceptors and possibly an M5-like receptor. Z-338 has been shown to be safe in phase I trials involving healthy volunteers in Europe and Japan and in an early phase II trial conducted in patients with functional dyspepsia. Z-338 continues to undergo phase II development.

IT 185104-11-4P, Z-338 185106-16-5P 211999-70-1P 403651-06-9P
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prokinetic thiazolecarboxamide derivative Z-338 synthesis, pharmacokinetics, and pharmacol. activity)

RN 185104-11-4 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 185106-16-5 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]- (CA INDEX NAME)



RN 211999-70-1 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM. 1

CRN 185106-16-5
CMF C21 H30 N4 O5 S



CM 2

CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 403651-06-9 CAPLUS
CN 4-Thiazolecarboxamide, N-[2-[bis(1-methylethyl)amino]ethyl]-2-[(2-hydroxy-4,5-dimethoxybenzoyl)amino]-, trihydrate (9CI) (CA INDEX NAME)



●3 H_2O

REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT